First patient dosed in trial of novel drug targeting limb-threatening artery disease
The trial will enroll up to 42 patients in Finland across four cohorts
The trial will enroll up to 42 patients in Finland across four cohorts
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The approval comes after a systematic review of published literature
Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
Subscribe To Our Newsletter & Stay Updated